Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesAltimmune Inc

Altimmune Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.94 USD -0.18 ( 8.49%)
Last update at 2026-11-10T21:04:00Z
VOLUME
3981851
Market Cap
463.17M

Momentum Score

…

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.90
Low
2.13
High
52 Week Price Range
2.87
Low
7.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Altimmune is a clinical-stage biotechnology company developing vaccines and immunotherapies with a focus on respiratory and liver-targeted approaches. Its long-term growth drivers include clinical data readouts, platform applicability to mucosal immunity that may benefit protection against respiratory pathogens, and potential partnerships or licensing opportunities. The company appears positioned to create multiple development pathways if clinical results support safety and efficacy.
Key investment risks include absence of approved products, dependence on successful trial outcomes, likely need for additional financing with potential shareholder dilution, and regulatory uncertainty investors should monitor.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.12
Dividend Yield
-
Revenue TTM
0.04M
Revenue Per Share
-
Gross Profit TTM
-66.39M
Debt / Equity
0.16
ROE
-50.57%
Net Debt
-8.07M
ROCE
-35.71%
Diluted EPS TTM
-1.00

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -88.77M -95.06M -88.45M -84.91M -97.09M
Net income -88.09M -95.06M -88.45M -84.71M -96.17M
Selling general administrative 28.10M 20.97M 18.14M 17.13M 15.41M
Gross profit -0.07M 0.02M 0.43M -0.07M 4.41M
Reconciled depreciation 0.11M 0.24M 0.48M -0.20M 0.55M
Ebit -94.60M -95.05M -88.41M -87.74M -96.91M
Ebitda -94.49M -94.81M -87.94M -84.90M -85.72M
Depreciation and amortization 0.11M 0.24M 0.48M 2.84M 11.20M
Non operating income net other - - - - -0.17M
Operating income -94.49M -103.17M -95.93M -87.74M -96.91M
Other operating expenses 94.53M 103.19M 96.36M 87.67M 89.95M
Interest expense 1.64M 0.01M 0.04M 0.01M 0.01M
Tax provision -0.68M 0.00M 0.00M -0.20M 0.00M
Interest income 7.54M 8.07M 7.35M 2.87M 0.20M
Net interest income 5.91M 8.06M 7.32M 2.86M 0.20M
Non recurring - - - - 11.37M
Income tax expense -0.68M - 0.31M -0.20M -0.92M
Total revenue 0.04M 0.02M 0.43M -0.07M 4.41M
Total operating expenses 94.53M 103.19M 96.36M 87.67M 89.95M
Cost of revenue 0.11M 0.24M 0.48M 0.07M -
Total other income expense net 5.71M 8.11M 7.48M 2.83M -0.18M
Net income from continuing ops -88.09M -95.06M -88.45M -84.71M -97.09M
Net income applicable to common shares - - - -84.71M -97.09M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 279.93M 139.31M 210.64M 206.93M 218.86M
Intangible assets - - - 12.42M 12.42M
Other current assets 3.00M 2.25M 6.82M 5.36M 13396.50M
Total liab 55.04M 15.80M 16.54M 21.64M 19.73M
Total stockholder equity 224.89M 123.51M 194.10M 185.29M 199.13M
Other current liab 12.02M 9.98M 9.58M 11.80M 6.09M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -649.48M -561.39M -466.33M -377.88M -293.17M
Other liab - - - 3.91M 0.33M
Other assets - - 0.00M 0.02M 0.07M
Cash 43.76M 36.93M 135.16M 111.10M 190.30M
Total current liabilities 15.00M 10.47M 12.14M 17.05M 18.28M
Current deferred revenue - - 0.00M - 9.74M
Net debt -8.07M -35.24M -134.49M -109.97M -188.77M
Short term debt 0.26M 0.28M 0.50M 0.45M 0.41M
Short long term debt total 35.69M 1.68M 0.67M 1.12M 1.54M
Other stockholder equity 879.29M 689.86M 665.43M 568.40M 497.34M
Property plant equipment - - - 1.68M 1.45M
Total current assets 278.19M 137.25M 209.53M 192.81M 204.13M
Net tangible assets - - - 172.87M 186.72M
Short term investments 229.70M 94.97M 62.70M 73.78M 0.00M
Net receivables 1.74M 3.12M 4.85M 2.54M 5.84M
Long term debt 34.29M - - - 1.45M
Inventory - - - 0.03M -13388.52M
Accounts payable 2.72M 0.21M 2.07M 4.80M 2.03M
Accumulated other comprehensive income -4.93M -4.97M -5.00M -5.23M -5.04M
Common stock total equity - - - - 0.00M
Retained earnings total equity - - - - -293.17M
Non currrent assets other 1.43M 1.64M 0.10M 0.61M 0.87M
Non current assets total 1.74M 2.05M 1.11M 14.12M 14.74M
Capital lease obligations 1.40M 1.68M 0.67M 1.12M 1.54M
Long term debt total - - - - 1.45M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -132.46M -28.39M 13.73M -73.40M 99.83M
Change to liabilities - - - 2.77M -0.88M
Total cashflows from investing activities -132.47M -28.39M 13.73M -73.40M 87.52M
Net borrowings 35.00M 0.00M - - -
Total cash from financing activities 206.84M 10.04M 86.11M 56.78M 65.10M
Change to operating activities - - - 8.04M -8.21M
Net income -88.09M -95.06M -88.45M -84.71M -97.09M
Change in cash 6.83M -98.19M 24.03M -79.20M 74.38M
Begin period cash flow 36.97M 135.16M 111.13M 190.34M 115.95M
End period cash flow 43.80M 36.97M 135.16M 111.13M 190.33M
Total cash from operating activities -67.53M -79.85M -75.81M -62.59M -78.24M
Issuance of capital stock 173.73M 9.99M 86.82M 56.35M 65.04M
Depreciation 0.11M 0.24M 0.48M -0.20M 0.55M
Other cashflows from investing activities - - - - -0.19M
Change to inventory - - 0.00M - -
Change to account receivables 2.06M 1.74M -2.31M 0.26M 4.18M
Sale purchase of stock 0.29M 0.30M 0.21M 0.18M 224.47M
Other cashflows from financing activities -0.71M 0.05M -0.50M 0.25M -224.41M
Change to netincome - - - 8.22M 18.55M
Capital expenditures 0.01M 0.00M 0.05M 0.13M 12.31M
Change receivables - - - - 4.18M
Cash flows other operating - - - - -3.55M
Cash and cash equivalents changes - - - - 74.38M
Change in working capital 6.75M 4.48M -8.27M 14.11M -0.25M
Stock based compensation 16.08M 14.39M 10.64M 8.10M 5.52M
Other non cash items -1.70M -3.90M 9.79M 0.12M 0.70M
Free cash flow -67.55M -79.85M -75.86M -62.71M -90.55M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ALT
Altimmune Inc		 -0.18
8.49%		 1.94 - 8.18 11296.94 2.06 5497.72 11.93
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Altimmune Inc

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

910 Clopper Road, Gaithersburg, MD, United States, 20878

240 654 1450

https://altimmune.com

57

Name Title Year Born
Dr. Vipin K. Garg Ph.D. Pres, CEO & Director 1958
Mr. Richard I. Eisenstadt M.B.A. Chief Financial Officer 1958
Dr. M. Scot Roberts Ph.D. Chief Scientific Officer 1959
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS Chief Medical Officer 1953
Mr. Bertrand Georges Ph.D. Chief Technology Officer NA
Mr. Tony Blandin B.S. VP of Quality & Compliance Management NA
Mr. José Ochoa Chief Bus. Officer NA
Mr. Kent A. Tapper BSEE Corp. Controller 1957
Dr. Vipin K. Garg Ph.D. President, CEO & Director 1958
Mr. Raymond M. Jordt M.B.A. Chief Business Officer 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…